HGH Fragment 176-191
Also known as: Frag 176-191, HGH Frag, AOD-9401
Key Facts: HGH Fragment 176-191
- Category
- Weight Loss
- FDA Status
- Not FDA Approved
- Clinical Status
- Investigational - Research ongoing
- Administration
- Subcutaneous injection on empty stomach
- Typical Dose
- 250-500 mcg daily
- Frequency
- 1-2x daily, fasted
- Duration
- 8-12 weeks
Mechanism of Action
Fragment 176-191 mimics the way natural HGH regulates fat metabolism but without adverse effects on blood sugar or growth. It stimulates lipolysis and inhibits lipogenesis, specifically targeting adipose tissue.
Research Summary
Studies show enhanced fat loss, particularly in abdominal area. Research demonstrates no impact on glucose metabolism or IGF-1 levels. Works synergistically with diet and exercise for body composition improvement.
Dosing Information
Typical Dosingⓘ
Community experience
250-500 mcg daily
200-600 mcg daily
1-2x daily, fasted
Fat-burning fragment of HGH. Take on empty stomach. Often split into morning and pre-bed doses.
Research Dosingⓘ
Scientific studies
Doses from research protocols
Doses from Studies
250-500 mcg daily
Often split AM and pre-workout
Duration
8-12 weeks
Administration
Subcutaneous injection on empty stomach
Timing & Administration
Best Time to Take
Before bed or morning (fasted)
Follow specific peptide protocol
Food Recommendation
Take on empty stomach
Why This Timing?
GH-related peptides work best on an empty stomach to maximize growth hormone release.
Possible Side Effects
Not everyone experiences these effects. Individual responses vary based on dosage, duration, and personal factors.
- ●Generally well-tolerated
- ●Injection site reactions
- ●Mild headache
- ●Nausea
- ●Does NOT cause typical HGH side effects
- ●No effect on IGF-1 levels
- ●GRAS status
References
- https://pubmed.ncbi.nlm.nih.gov/11713213/
- https://pubmed.ncbi.nlm.nih.gov/11673763/
- https://pubmed.ncbi.nlm.nih.gov/10950816/
Research This Peptide Further
Frequently Asked Questions
What does HGH Fragment 176-191 do?
The lipolytic fragment of human growth hormone. Contains the fat-burning portion of HGH without effects on blood sugar or cell proliferation.
How does HGH Fragment 176-191 work?
Fragment 176-191 mimics the way natural HGH regulates fat metabolism but without adverse effects on blood sugar or growth. It stimulates lipolysis and inhibits lipogenesis, specifically targeting adipose tissue.
Is HGH Fragment 176-191 FDA approved?
No, HGH Fragment 176-191 is not currently FDA approved. Current status: Investigational - Research ongoing
What are the side effects of HGH Fragment 176-191?
Reported side effects include: Generally well-tolerated, Injection site reactions, Mild headache, Nausea, Does NOT cause typical HGH side effects. Individual responses vary based on dosage, duration, and personal health factors.
What is the typical dose of HGH Fragment 176-191?
Community-reported common dose: 250-500 mcg daily (1-2x daily, fasted). Range: 200-600 mcg daily. Administration: Subcutaneous injection on empty stomach. Community-reported doses. Not medical advice. Consult healthcare provider.
Related Peptides
Peptides commonly compared with HGH Fragment 176-191 or used in similar applications.
Semaglutide
FDAA GLP-1 receptor agonist with multiple FDA approvals including weight loss, T2D, CV risk reduction, and kidney protection. Wegovy pill approved Dec 2025 as first oral GLP-1 for weight loss.
Weight LossTirzepatide
FDAA dual GIP/GLP-1 receptor agonist representing the next generation of incretin-based therapies. Shows superior weight loss compared to semaglutide in head-to-head trials. First medication approved for obstructive sleep apnea.
Weight LossRetatrutide
Clinical TrialsA triple agonist targeting GLP-1, GIP, and glucagon receptors. Phase 3 trials show up to 28.7% weight loss (71 lbs average), the highest of any obesity drug. Expected FDA approval late 2026 to early 2027.
Weight LossOrforglipron
FDAAn oral non-peptide GLP-1 receptor agonist. FDA approved April 1, 2026 under the brand name Foundayo - the first daily oral GLP-1 pill for weight loss. Distribution began April 6, 2026. FDA subsequently requested additional post-approval safety data.
Weight LossCagriSema
Clinical TrialsA combination of semaglutide and cagrilintide (amylin analog). The most effective weight loss drug candidate, showing 22.7% body weight reduction in Phase 3 trials - superior to any single-agent GLP-1.
Weight LossAOD-9604
Clinical TrialsA modified fragment of human growth hormone (amino acids 177-191) studied for fat metabolism effects without the broader hormonal effects of full GH.
Weight LossWant updates on HGH Fragment 176-191 research?
Subscribe to get notified when we add new research findings, protocol updates, and related peptide information.